Janssen’s Stelara® (ustekinumab) has received expanded approval to treat patients who are at least six years old and have active psoriatic arthritis.

• Stelara first received FDA approval in 2009, and is also indicated to treat psoriasis, Crohn’s disease, and ulcerative Prior to the expanded indication, it was only approved for psoriatic arthritis in adult patients.
• Recommended dosing for pediatric patients for the treatment of active psoriatic arthritis is based on the patient’s weight. The recommended route of administration is subcutaneous injection.